Vanda raises cash in anticipation of tasimelteon approval
This article was originally published in Scrip
Executive Summary
Vanda Pharmaceuticals is taking advantage of a spike in its stock price to sell 4.68 million shares following recent US FDA acceptance of its new drug application (NDA) for tasimelteon and the regulator's decision to grant priority review for the sleep disorder drug.